Opioid withdrawal syndrome: Emerging concepts and novel therapeutic targets

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 1, 2013, Pages 112-125

  Rehni, Ashish K ^a   Jaggi, Amteshwar S ^a   Singh, Nirmal ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Adenylyl cyclase superactivation; Opioid dependence; Opioid withdrawal syndrome; Pharmacological interventions

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACETYLMETHADOL; APREPITANT; BUSPIRONE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE[8-37]; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CHANNEL; CANNABIDIOL; CORTICOTROPIN RELEASING FACTOR; DRONABINOL; DYNORPHIN [1-13]; ESCITALOPRAM; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; HYDROMORPHONE; KETAMINE; LAMOTRIGINE; LEUKOTRIENE; MEMANTINE; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORADRENALIN; ONDANSETRON; OPIATE; PIOGLITAZONE; PROSTAGLANDIN; RAF PROTEIN; TELAPREVIR; TRAMADOL; UNCLASSIFIED DRUG; VARENICLINE;

BEHAVIOR; DRUG DEPENDENCE; DRUG EFFICACY; GENE EXPRESSION; HUMAN; LOCUS CERULEUS; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; OPIOID-RELATED DISORDERS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84875294188     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311312010017     Document Type: Review

References (201)

1. World Health Organization. WHO Expert Committee on Addiction-Producing Drugs. Thirteenth report, Geneva, 1964 (WHO Technical Report Series, No. 273).
2. World Health Organisation. WHO Report on Neuroscience of Psychoactive Substance Use and Dependence, Geneva, 2005 WHO.
3. Akil, H.; Lewis, J.W. Neurotransmitters and Pain Control. Pain and Headache, Basil, Karger, 1987, 9, 129-159.
4. Van Ree, J.M.; Gerrits, M.A.F.M.; Vanderschuren, L.J.M.J. Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacol. Rev., 1999, 51, 341-396.
5. Hardman, J.G., Limbird, L.E., Gilman, A.G. Goodman and Gilman's The pharmacological basis of therapeutics. McGraw Hill, New York, 2001.
6. World Health Organization. International Classification of Diseases,10thedition(ICD-10). http://www.who.int/classifications/apps/icd/icd10online/, 2007.
7. United Nations Office on Drugs and Crime. World Drug Report, 2007.
8. Clark, N.; Gospodarevskaya, E.; Harris, A.; Ritter, A. Estimating the Cost of Heroin Use in Victoria. Report to the Premier's Drug Prevention Council. Melbourne: Department of Human Services 2003.AvailableonlineatURL: http://www.druginfo.adf.org.au/hidden_articles/estimating_the_cos t_of_heroin_1.html39, 2003.
9. Collins, D.J.; Lapsley, H.M. The social costs of drug abuse in Australia in 1988 and 1992. Canberra, Australia, 1996.
10. Xie, X.; Rehm, J.; Single, E.; Robson, L.; Paul, J. The economic costs of Illicit drug use in Ontario, 1992. Electronic Health Economics letters, 1998, 2(1), 8-14.
11. Krantz, M.J.; Mehler, P.S. Treating opioid dependence growing implications for primary care. Arch. Intern. Med., 2004, 164, 277-288.
12. Lee, S.; Rosenberg, C.R.; Musacchio, M. Cross-dependence to opioid and a2-adrenergic receptor agonists in NG1O8-15 cells. FASEB J., 1987, 2, 52-5.
13. Amato, L.; Davoli, M.; Minozzi, S.; Ali, R.; Ferri, M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews (Online), 2005, 3, CD003409.
14. Doyon, S. Opiods. In: Tintinalli, J.E.; Kelen, G.D.; Stapczynski, J.S.; Ma, O.J.; Cline, D.M., Eds.; Emergency Medicine: A Comprehensive Study Guide. 6th ed. New York, NY: McGraw-Hill; 2004, Chapter 167.
15. Gowing, L.; Farrell, M.; Ali, R.; White, J.M. Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews (Online), 2008, 4, CD002024.
16. Gossop, M. Medically supervised withdrawal as stand-alone treatment. In E. C. Strain & M. L. Stitzer (Eds.), The treatment of opioid dependence (pp. 346-362). Baltimore: Johns Hopkins University Press, 2006.
17. Calsyn, D.A.; Malcy, J. A.; Saxon, A.J. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance. J. Subst. Abuse Treat., 2006, 30, 159-163.
18. Amato, L.; Minozzi, S.; Davoli, M.; Vecchi, S.; Ferri, M.M.; Mayet, S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews (Online), 2008, 4, CD005031.
19. Gonzalez, J.P.; Brogden, R.N. Naltrexone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs, 1988, 35, 192-213.
20. Gerra, G.; Fantoma, A.; Zaimovic, A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J. Psychopharmacol., 2006, 20, 806-814.
21. Nunes, E.V.; Rothenberg, J.L.; Sullivan, M.A.; Carpenter, K.M.; Kleber, H.D. Behavioral therapy to augment oral naltrexone for opioid dependence: A ceiling on effectiveness? Am. J. Drug Alcohol Abuse, 2006, 32, 503-517.
22. Fals-Stewart, W.; O'Farrell, T.J. Behavioral family counseling and naltrexone for male opioid-dependent patients. J. Consult. Clin. Psychol., 2003, 71, 432-442.
23. van de Brink, W.; Haasen, C. Evidence-based treatment of opioid-dependent patients. Can. J. Psychiatry, 2006, 51, 635-646.
24. Leshner, A. I. Drug addiction research: Moving toward the 21st century. Drug Alcohol Depend., 1998, 51, 5-7.
25. Farrell, M.; Ward, J.; Mattick, R.R.; Hall, W.; Stimson, G.V.; des Jarlais, D.; Gossop, M.; Strang, J. Methadone maintenance treatment in opiate dependence: A review. B.M.J., 1994, 309, 997-1001.
26. Ward, J.; Hall, W.; Mattick, R.P. Role of maintenance treatment in opioid dependence. Lancet, 1999, 353, 221-226.
27. Dole, V.P.; Nyswander, M. A medical treatment for diacetylmorphine (heroin) addiction: A clinical trial with methadone hydrochloride. JAMA, 1965, 193, 646-650.
28. O'Connor, P.G. Methods of detoxification and their role in treating patients with opioid dependence. JAMA, 2005, 294, 961-963.
29. Pond, S.M.; Kreek, M.J.; Tong, T.G.; Raghunath, J.; Benowitz, N.L. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J. Pharmacol. Exp. Ther., 1985, 233, 1-6.
30. Maxwell, S.; Shinderman, M.S. Optimizing long-term response to methadone maintenance treatment: A 152-week follow-up using higher-dose methadone. J. Addict. Dis., 2002, 21, 1-12.
31. Schottenfeld, R.S.; Chawarski, M.C.; Mazlan, M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: A randomized, double-blind, placebo-controlled trial. Lancet, 2008, 371, 2192-2200.
32. Clark, N.C.; Linteris, N.; Gijsbers, A.; Whelan, G.; Dunlop, A.; Ritter, A.; Ling, W.W. LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database of Systematic Reviews, 2002, 2, CD002210.
33. Wedham, E.F.; Bigelow, G.E.; Johnson, R.E.; Nuzzo, P.A.; Haigney, M.C.P. QT Interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch. Intern. Med., 2007, 167, 2469-2475.
34. Anglin, D.M.; Conner, B.T.; Annon, J.; Longshore, D. Longitudinal effects of LAAM and methadone maintenance on heroin addict behavior. J. Behav. Health Services Res., 2009, 36, 267-282.
35. Collins, G.B.; McAllister, M.S. Buprenorphine maintenance: A new treatment for opioid dependence. Cleveland Clinic Journal Of Medicine 2007, 74 (7), 514-520.
36. Haasen, C.; Verthein, U.; Degkwitz, P.; Berger, J.; Krausz, M.; Naber, D. Heroin assisted treatment for opioid dependence: Randomized controlled trial. Br. J. Psychiatry, 2007, 191, 55-62.
37. Collins, E.D.; Kleber, H.D.; Whittington, R.A.; Heitler, N.E. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA, 2005, 294 (8), 903-13.
38. Amato, L.; Minozzi, S.; Davoli, M.; Vecchi, S.; Ferri, M.M.; Mayet, S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews (Online), 2008, 4, CD004147.
39. Mayet, S.; Farrell, M.; Ferri, M.M.F.; Amato, L.; Davoli, M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database of Systematic Reviews (Online), 2004, 4, CD004330.
40. Jaffe, J.H. Pharmacological agents in treatment of drug dependence. In Psychopharmacology. The Third Generation of Progress, ed. by H. Y. Meltzer, 1987, 1605-1616, Raven Press, New York.
41. Ball, J. C.; Ross, A. Follow-up study of 105 patients who left treatment. In The Effectiveness of Methadone Maintenance Treatment. Patients, Programs, Services, and Outcome, ed. by J. C. Ball and A. Ross, 1991, 176-187, Springer-Verlag, New York.
42. Minozzi, S.; Amato, L.; Vecchi, S.; Davoli, M.; Kirchmayer, U.; Verster, A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews (Online), 2006, 2, CD001333.
43. Williams, J.T.; Christie, M.J.; Manzoni, O. Cellular and Synaptic Adaptations Mediating Opioid Dependence. Physiol. Rev., 2001, 81, 299-343.
44. Sullivan, M. A.; Comer, S. D.; Nunes, E. V. Pharmacology and clinical use of naltrexone. In E. C. Strain & M. L. Stitzer (Eds.), The treatment of opioid dependence, 2006, (pp. 295-320). Baltimore: Johns Hopkins University Press.
45. Kosten, T.R.; George, T.P. The Neurobiology of Opioid Dependence: Implications for Treatment. Research Reviews-The Neurobiology Of Opioid Dependence; Science & Practice Perspectives, 2002, 13-20.
46. Dahlstroem, A.; Fuxe, K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand., 1964, 232, 1-55.
47. Moore, R.Y.; Bloom, F.E. Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annu. Rev. Neurosci., 1979, 2, 113-168.
48. Foote, S.L.; Bloom, F.E.; Aston-Jones, G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol. Rev., 1983, 63, 844-914.
49. Maldonado, R.; Stinus, L.; Koob, G.F. (1996). Neuropsychopharmacology of opiate dependence. In R. Maldonado, L. Stinus, & G. F. Koob (Eds.), Neurobiological Mechanisms of Opiate Withdrawal, Ch. 5 (pp. 77±124). New York: Springer.
50. Kreek, M.J.; Koob, G.F. Drug dependence: Stress and dysregulation of brain reward pathways. Drug and Alcohol Dependence, 1998, 51(1-2), 23-47.
51. Liu, J.G.; Anand, K.J. Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res. Brain Res. Rev., 2001, 38, 1e19.
52. Nestler, E.J. Historical review: Molecular and cellular mechanisms of opiate and cocaine addiction. Trends in Pharmacol. Sci., 2004, 25, 210-218.
53. Mostany, R.; Diaz, A.; Valdizan, E.M.; Rodrguez-Munoz, M.; Garzon, J.; Hurle, M.A. Supersensitivity to u-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Ga protein subunits. Neuropharmacol, 2008, 54, 989-997.
54. George, S.R.; Fan, T.; Xie, Z.; Tse, R.; Tam, V.; Varghese, G.; O'Dowd, B.F. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem., 2000, 275, 26128-26135.
55. Fan, T.; Varghese, G.; Nguyen, T.; Tse, R.; O'Dowd, B.F., George, S.R. A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J. Biol. Chem., 2005, 280, 38478-38488.
56. Sharma, K.S.; Klee, W.A.; Nirenberg, M. Opiate-dependent modulation of adenylate cyclase. Proc. Natl. Acad. Sci. U.S.A., 1977, 74, 3365-3369.
57. Law, P.Y.; Hom, D.S.; Loh, H.H. Loss of opiate receptor activity in neuroblastoma X glioma NG108-15 hybrid cells after chronic opiate treatment. A multiple-step process. Mol. Pharmacol, 1982, 22, 1-4.
58. Koob, G.F.; Bloom, F.E. Cellular and molecular mechanisms of drug dependence. Science, 1988, 242, 715-723.
59. Pineyro, G.; Archer-Lahlou, E. Ligand-specific receptor states: implications for opiate receptor signalling and regulation. Cell. Signal, 2007, 19, 8-19.
60. Delfs, J.M.; Zhu, Y.; Druhan, J.P.; Aston-Jones, G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature, 2000, 403, 430-434.
61. Chakrabarti, S.; Rivera, M.; Yan, S.Z.; Tang, W.J.; Gintzler, A.R. Chronic morphine augments G(beta)(gamma)/Gs(alpha) stimulation of adenylyl cyclase: relevance to opioid tolerance. Mol. Pharmacol, 1998, 54, 655-662.
62. Chakrabarti, S.; Wang, L.; Tang, W.J.; Gintzler, A.R. Chronic morphine augments adenylyl cyclase phosphorylation: relevance to altered signaling during tolerance/dependence. Mol. Pharmacol, 1998, 54, 949-953.
63. Varga, E.V.; Rubenzik, M.K.; Stropova, D.; Sugiyama, M.; Grife, V.; Hruby, V.J.; Rice K.C.; Roeske, W.R.; Yamamura, H.I. Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic δ-opioid receptor stimulation. J. Pharmacol. Exp. Ther., 2003, 306, 109-115.
64. Crain, S.M.; Shen, K.F. Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance and dependence. Neurochem. Res., 1996, 21, 1347-1351.
65. Tso, P.H.; Wong, Y.H. Opioid-induced adenylyl cyclase supersensitization in human embryonic kidney 293 cells requires pertussis toxin sensitive G proteins other than G(i1) and G(i3). Neurosci. Lett., 2001, 299, 25-28.
66. Avidor-Reiss, T.; Nevo, I.; Levy, R.; Pfeuffer, T.; Vogel, Z. Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gβ. J. Biol. Chem., 1996, 271, 21309-21315.
67. Chavkin, C; McLaughlin, J.P.; Celver, J.P. Regulation of opioid receptor function by chronic agonist exposure. Mol. Pharmacol, 2001, 60, 20-25.
68. Liu, J.G.; Ruckle, M.B.; Prather, P.L. Constitutively active mu opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala2,N-Me-Phe4,Gly-ol5]enkephalin. J. Biol. Chem., 2001, 276, 37779-37786.
69. Yu, L. Protein kinase modulation of mu opioid receptor signaling. Cell. Signal, 1996, 8, 371-374.
70. Nestler, E.J.; Aghajanian, G.K. Molecular and cellular basis of addiction. Science (Wash DC), 1997, 278, 58-63.
71. Lu, L.; Liu, D.; Ceng, X.; Ma, L. Differential role of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur. J. Neurosci., 2000, 12, 4398-4404.
72. Zhao, H.; Loh, H.H.; Law, P.Y. Adenylyl cyclase superactivation induced by long-term treatment with opioid agonists is dependent on receptor localized within lipid rafts and is independent of receptor internalization. Mol. Pharmacol, 2006, 69, 1421-1432.
73. Lisanti, M.P.; Scherer, P.E.; Vidugiriene, J.; Tang, Z.L.; Hermanoski-Vosatka, A.; Tu, Y.H.; Cook, R.F.; Sargiacomo, M. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J. Cell. Biol, 1994, 126, 111-126.
74. Avidor-Reiss, T.; Nevo, I.; Saya, D.; Bayewitch, M.; Vogel, Z. Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J. Biol. Chem., 1997, 272, 5040-5047.
75. Chakrabarti, S.; Oppermann, M.; Gintzler, A.R. Chronic morphine induces the concomitant phosphorylation and altered association of multiple signaling proteins: a novel mechanism for modulating cell signaling. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 4209-4214.
76. Zhang, L.; Zhao, H.; Yu Qiu; Loh, H.H.; Law, P.Y. Src phosphorylation of u-receptor is responsible for the receptor switching from an inhibitory to a stimulatory signals. J. Biol. Chem., 2009, 284(4), 1990-2000.
77. Rehni, A.K.; Singh, N. Modulation of src-kinase attenuates naloxone-precipitated opioid withdrawal syndrome in mice. Behav. Pharmacol, 2011, 22(2), 182-190.
78. Homayoun, H.; Khavandgar, S.; Mehr, S.E.; Namiranian, K.; Dehpour, A.R. The effects of FK506 on the development and expression of morphine tolerance and dependence in mice. Behav. Pharmacol, 2003, 14(2), 121-127.
79. Li, S.; Lee, M.L.; Bruchas, M.R.; Chan, G.C.; Storm, D.R.; Chavkin, C. Calmodulin-stimulated adenylyl cyclase gene deletion affects morphine responses. Mol. Pharmacol, 2006, 70(5), 1742-1749.
80. Cridland, R.A.; Henry, J.L. Intrathecal administration of CGRP in the rat attenuates a facilitation of the tail flick reflex induced by either substance P or noxious cutaneous stimulation. Neurosci. Lett., 1989, 102, 241-246.
81. Yu, L.C.; Hansson, P.; Lundeberg, T. The calcitonin gene-related peptide antagonist CGRP8-37 increases the latency to withdrawal responses in rats. Brain Res., 1994, 653, 223-230.
82. Galeazza, M.T.; Garry, M.G.; Yost, H.J.; Strait, K.A.; Hargreaves, K.M.; Seybold, V.S. Plasticity in the synthesis and storage of substance P and calcitonin gene-related peptide in primary afferent neurons during peripheral inflammation. Neuroscience, 1995, 66, 443-458.
83. Menard, D.P.; van Rossum, D.; Kar, S.; Jolicoeur, F.B.; Jhamandas, K.; Quirion, R. Tolerance to the antinociceptive properties of morphine in the rat spinal cord: alteration of calcitonin gene-related peptide like immunostaining and receptor binding sites. J. Pharmacol. Exp. Ther., 1995, 273, 887-894.
84. Menard, D.P.; van Rossum, D.; Kar, S.; Quirion, R. Alteration of calcitonin gene related peptide and its receptor binding sites during the development of tolerance to mu and delta opioids. Can. J. Physiol. Pharmacol, 1995, 73, 1089-1095.
85. Ma, W.; Zheng, W.H.; Kar, S.; Quirion, R. Morphine treatment induced calcitonin gene-related peptide and substance P increases in cultured dorsal root ganglion neurons. Neuroscience, 2000, 99, 529-539.
86. Belanger, S.; Ma, W.; Chabot, J.G.; Quirion, R. Expression of calcitonin gene-related peptide, substance P and protein kinase C in cultured dorsal root ganglion neurons following chronic exposure to mu, delta and kappa opiates. Neuroscience, 2002, 115, 441-453.
87. Tiong, G.K.; Pierce, T.L.; Olley, J.E. Sub-chronic exposure to opiates in the rat: effects on brain levels of substance P and calcitonin gene related peptide during dependence and withdrawal. J. Neurosci. Res., 1992, 32, 569-575.
88. Welch, S.P.; Bass, P.P.; Olson, K.G.; Pugh, G. Morphine-induced modulation of calcitonin gene-related peptide levels. Pharmacol. Biochem. Behav., 1992,.43, 1107-1116.
89. Trang, T.; Sutak, M.; Quirion, R.; Jhamandas, K. The role of spinal neuropeptides and prostaglandins in opioid physical dependence. Br. J. Pharmacol., 2002, 136, 37-48.
90. Nestler, E.J. Under siege: the brain on opiates. Neuron, 1996, 16, 897-900.
91. Lane-Ladd, S.B.; Pineda, J.; Boundy, V.A.; Pfeuffer, T.; Krupinski, J.; Aghajanian, G.K.; Nestler, E.J. CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence. J. Neurosci., 1997, 17, 7890-7901.
92. Gibbins, I.L.; Furness, J.B.; Costa, M. Pathway-specific patterns of the co-existence of substance P, calcitonin gene-related peptide, cholecystokinin and dynorphin in neurons of the dorsal root ganglia of the guinea-pig. Cell. Tissue Res., 1987, 248, 417-437.
93. Gibbins, I.L.; Morris, J.L. Co-existence of neuropeptides in sympathetic, cranial autonomic and sensory neurons innervating the iris of the guinea-pig. J. Auton. Nerv. Syst., 1987, 21, 67-82.
94. Merighi, A.; Polak, J.M.; Theodosis, D.T. Ultrastructural visualization of glutamate and aspartate immunoreactivities in the rat dorsal horn, with special reference to the co-localization of glutamate, substance P and calcitonin-gene related peptide. Neuroscience, 1991, 40, 67-80.
95. Kangrga, I.; Larew, J.S.; Randic, M. The effects of substance P and calcitonin gene-related peptide on the efflux of endogenous glutamate and aspartate from the rat spinal dorsal horn in vitro. Neurosci. Lett., 1990, 108, 155-160.
96. Murase, K.; Ryu, P.D.; Randic, M. Excitatory and inhibitory amino acids and peptide-induced responses in acutely isolated rat spinal dorsal horn neurons. Neurosci. Lett., 1989, 103, 56-63.
97. Dunbar, S.; Yaksh, T.L. Effect of spinal infusion of l-NAME, a nitric oxide synthase inhibitor, on spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Neurosci. Lett., 1996, 207, 33-36.
98. Jhamandas, K.H.; Marsala, M.; Ibuki, T.; Yaksh, T.L. Spinal amino acid release and precipitated withdrawal in rats chronically infused with spinal morphine. J. Neurosci., 1996, 16, 2758-2766.
99. Oku, R.; Satoh, M.; Fujii, N.; Otaka, A.; Yajima, H.; Takagi, H. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res., 1987, 403, 350-354.
100. Seybold, V.S.; McCarson, K.E.; Mermelstein, P.G.; Groth, R.D.; Abrahams, L.G. Calcitonin gene-related peptide regulates expression of neurokinin1 receptors by rat spinal neurons. J. Neurosci., 2003, 23, 1816-1824.
101. Dunbar, S.A.; Karamov, I.G.; Buerkle, H. The effect of spinal ibuprofen on opioid withdrawal in the rat. Anesth. Analg., 2000, 91, 417-422.
102. Trang, T.; Sutak, M.; Quirion, R.; Jhamandas, K. Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of naloxone-precipitated opioid withdrawal. Br. J. Pharmacol., 2003, 140, 295-304.
103. Hay, C.; de Belleroche, J. Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord. Neuroreport, 1997, 8, 1249-1251.
104. Capasso, A. Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology, 1999, 38, 871-877.
105. Capasso, A.; Sorrentino, L. Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Eur. J. Pharmacol., 1997, 330, 199-204.
106. Walters, C.L.; Wang, B.C.; Godfrey, M.; Sun, D.; Funk, C.D.; Blendy, J.A. Augmented responses to morphine and cocaine in mice with a 12-lipoxygenase gene disruption. Psychopharmacology (Berl), 2003, 170, 124-131.
107. Ledent, C.; Valverde, O.; Cossu, G.; Petitet, F.; Aubert, J.F.; Beslot, F.; Böhme, G.A.; Imperato, A.; Pedrazzini, T.; Roques, B.P.; Vassart, G.; Fratta, W.; Parmentier, M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 1999, 283, 401-404.
108. Rubino, T.; Massi, P.; Vigano, D.; Fuzio, D.; Parolaro, D. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci., 2000, 66, 2213-2219.
109. Mas-Nieto, M.; Pommier, B.; Tzavara, E.T.; Caneparo, A.; Da Nascimento, S.; Le Fur, G.; Roques, B.P.; Noble, F. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br. J. Pharmacol., 2001, 132, 1809-1816.
110. Samuelsson, B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science, 1983, 220, 568-575.
111. Rehni, A.K.; Bhateja, P.; Singh, T.G.; Singh, N. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome. Behav. Pharmacol., 2008, 19(3), 265-269.
112. Rehni, A.K.; Singh, I.; Singh, N.; Bansal, N.; Bansal, S.; Kumar, M. Pharmacological modulation of leukotriene D(4) attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome. Eur. J. Pharmacol., 2008, 598(1-3), 51-56.
113. Egertova, M.; Giang, D.K.; Cravatt, B.F.; Elphick, M.R. A new perspective on cannabinoid signaling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc. R. Soc. Lond. B. Biol. Sci., 1998, 265, 2081-2085.
114. Felder, C.C.; Joyce, K.E.; Briley, E.M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A.L.; Mitchell, R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 1995, 48, 443-450.
115. Farquhar-Smith, W.P.; Egertova, M.; Bradbury, E.J.; McMahon, S.B.; Rice, A.S.; Elphick, M.R. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol. Cell. Neurosci., 2000, 15, 510-521.
116. Cichewicz, D.L.; Martin, Z.L.; Smith, F.L.; Welch, S.P. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose response analysis and receptor identification. J. Pharmacol. Exp. Ther., 1999, 289, 859-867.
117. Massi, P.; Vaccani, A.; Romorini, S.; Parolaro, D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J. Neuroimmunol., 2001, 117, 116-124.
118. Salio, C.; Fischer, J.; Franzoni, M.F.; Mackie, K.; Kaneko, T.; Conrath, M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport, 2001, 12, 3689-3692.
119. Del, A.I.; Navarro, M.; Bilbao, A.; Ferrer, B.; Piomelli, D.; Rodriguez, D.F. Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404. Eur. J. Pharmacol., 2002, 454, 103-104.
120. Gonzalez, S.; Fernandez-Ruiz, J.; Sparpaglione, V.; Parolaro, D.; Ramos, J.A. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend., 2002, 66, 77-84.
121. Gonzalez, S.; Schmid, P.C.; Fernandez-Ruiz, J.; Krebsbach, R.; Schmid, H.H.; Ramos, J.A. Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats. Addict. Biol., 2003, 8, 159-166.
122. Danysz, W.; Parsons, C. G.; Bresink, I.; Quack, G. Glutamate in CNS disorders: A revived target for drug development. Drug News Perspect., 1995, 8, 261-277.
123. Cappendijk, S.L.; De Vries, R.; Dzoljic, M.R. Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndromeinmorphine-dependentmice.Eur. Neuropsychopharmacol., 1993, 3, 111-116.
124. Higgins, G.A.; Nguyen, P.; Sellers, E.M. The NMDA antagonist dizocilpine (MK801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. Life Sci., 1992, 50, PL167-PL172.
125. Popik, P.; Layer, R.T.; Fossom, L.; Benveniste, M.; Getter-Douglas, B.; Witkin, J.M.; Skolnick, P. NMDA antagonist properties of the putative antiaddicitive drug, ibogaine. J. Pharmacol. Exp. Ther., 1995, 275, 753-760.
126. Rasmussen, K.; Fuller, R.W.; Stockton, M.E.; Perry, K.W.; Swinford, R.M.; Ornstein, P.L. NMDA receptor antagonists supress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur. J. Pharmacol., 1991, 197, 9-16.
127. Tanganelli, S.; Antonelli, T.; Morari, M.; Bianchi, C; Beani, L. Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neurosci. Lett., 1991, 122, 270-272.
128. Trujillo, K.A.; Akil, H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science, 1991, 251, 85-87.
129. Elliott, K.; Minami, N.; Kolesnikov, Y.A.; Pasternak, G.W.; Inturrisi, C.E. The NMDA receptor antagonists, LY74614 and MK801, and the nitric oxide synthase inhibitor, ng-nitro-l-arginine, attenuate analgesic tolerance to the u-opioid morphine but not to k-opioids. Pain, 1994, 56, 69-75.
130. Tiseo, P.J.; Cheng, J.; Pasternak, G.W.; Inturrisi, C.E. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor. J. Pharmacol. Exp. Ther., 1994, 268, 195-201.
131. Tiseo, P.J.; Inturrisi, C.E. Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J. Pharmacol. Exp. Ther., 1993, 264, 1090-1096.
132. Popik, P.; Skolnick, P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav., 1996, 53, 791-798.
133. Koyuncuoglu, H.; Saydam, B. The treatment of heroin addicts with dextromethorphan. A double-blind comparison of dextromethorphan with chloropromazine. Int. J. Clin. Pharmacol. Ther. Toxicol, 1990, 28, 147-152.
134. Lotsof, H.S. Ibogaine in the treatment of chemical depencency disorders: Clinical perspectives. Bull. Multidisciplinary Association for Psychedelic Studies, 1995, 5, 16-27.
135. Lim, G.; Wang, S.; Zeng, Q.; Sung, B.; Yang, L.; Mao, J. Expression of spinal NMDA receptor and PKCgamma after chronic morphine is regulated by spinal glucocorticoid receptor. J. Neurosci., 2005, 25(48), 11145-11154.
136. Drdla, R.; Gassner, M.; Gingl, E.; Sandkühler, J. Induction of synaptic long-term potentiation after opioid withdrawal. Science, 2009, 325, 207-210.
137. Bhargava, H.N. The effects of divalent ions on morphine analgesia and abstinence syndrome in morphine-tolerant and -dependent mice. Psychopharmacology, 1978, 57, 223.
138. Harris, R.A.; Yamamoto, H.; Loh, H.H.; Way, E.L. Discrete changes in brain calcium with morphine analgesia, tolerance-dependence, and abstinence. Life Sci., 1977, 20, 501.
139. Baeyens, J.M.; Esposito, E.; Ossowska, G.; Samanin, R. Effects of peripheral and central administration of calcium channel blockers in the naloxone-precipitated abstinence syndrome in morphine-dependent rats. Eur. J. Pharmacol, 1987, 137, 9.
140. Shibasaki, M.; Katsura, M.; Kurokawa, K.; Torigoe, F.; Ohkuma, S. Regional differences of L-type high voltage-gated calcium channel subunit expression in the mouse brain after chronic morphine treatment. J. Pharmacol. Sci., 2007, 105, 177-183.
141. Ramkumar, V.; El-Fakahany, E.E. Prolonged morphine treatment increases rat brain dihydropyridine binding sites: possible involvement in development of morphine dependence. Eur. J. Pharmacol, 1988, 146, 73-83.
142. Tokuyama, S.; Ho, I.K. Effects of diltiazem, a Ca2+ channel blocker, on naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats. Psychopharmacology (Berl), 1996, 125(2), 135-140.
143. Tokuyama, S.; Ho, I.K. Inhibitory effects of diltiazem, an L-type Ca2+ channel blocker, on naloxone-increased glutamate levels in the locus coeruleus of opioid-dependent rats. Brain Res., 1996, 722(1-2), 212-216.
144. Hanson, P.I.; Schulman, H. Neuronal Ca21/calmodulin-dependent protein kinases. Annu. Rev. Biochem., 1992, 61, 559-601.
145. Koch, T.; Kroslak, T.; Mayer, P.; Raulf, E.; Hollt, V. Site mutation in the rat u-opioid receptor demonstrates the involvement of calcium/calmodulin-dependent protein kinase II in agonist-mediated desensitization. J. Neurochem., 1997, 69, 1767-1770.
146. Lu, L.; Zeng, S.; Liu, D.; Ceng, X. Inhibition of the amygdala and hippocampal calcium/calmodulin-dependent protein kinase II attenuates the dependence and relapse to morphine differently in rats. Neurosci. Lett., 2000, 291(3), 191-195.
147. Lou, L.; Zhou, T.; Wang, P.; Pei, G. Modulation of Ca21/Calmodulin-dependent protein kinase II activity by acute and chronic morphine administration in rat hippocampus: differential regulation of a and β isoforms. Mol. Pharmacol, 1999, 55, 557-563.
148. Schuman, E.M.; Madison, D.V. Nitric oxide and synaptic function. Annu. Rev. Neurosci., 1994, 17, 153-183.
149. Cuellar, B.; Fernández, A.P.; Lizasoain, I.; Moro, M.A.; Lorenzo, P.; Bentura, M.L.; Rodrigo, J.; Leza, J.C. Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal. Psychopharmacology, 2000, 148, 66-73.
150. Kolesnikov, Y.A.; Pick, C.G.; Ciszewska, G.; Pasternak, G.W. Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor. Proc. Natl. Acad. Sci. U.S.A., 1993, 90, 5162-5166.
151. Leza, J.C; Lizasoain, I.; Cuellar, B.; Moro, M.A.; Lorenzo, P. Correlation between brain nitric oxide synthase activity and opiate withdrawal, Naunyn Schmiedeberg's Arch. Pharmacol, 1996, 353, 349-354.
152. Torrecilla, M.; Marker, C.L.; Cintora, S.C.; Stoffel, M.; Williams, J.T.; Wickman, K. G-protein-gated potassium channels containing Kir3.2 and Kir3.3 subunits mediate the acute inhibitory effects of opioids on locus ceruleus neurons. J. Neurosci., 2002, 22, 4328-4334.
153. Cruz, H.G.; Berton F.; Sollini M.; Blanchet C; Pravetoni M.; Wickman K.; Luscher C. Absence and Rescue of Morphine Withdrawal in GIRK/Kir3 Knock-out Mice. J. Neurosci., 2008, 28(15), 4069-4077
154. Labouebe, G.; Lomazzi, M.; Cruz, H.G.; Creton, C; Lujan, R.; Li, M.; Yanagawa, Y.; Obata, K.; Watanabe, M.; Wickman, K.; Boyer, S.B.; Slesinger, P.A.; Luscher, C. RGS2 modulates coupling between GABA(B) receptors and GIRK channels in dopamine neurons of the ventral tegmental area. Nat. Neurosci., 2007, 10, 1559-1568.
155. Ikeda, K.; Kobayashi, T.; Kumanishi, T.; Niki, H.; Yano, R. Involvement of G-protein-activated inwardly rectifying K (GIRK) channels in opioid induced analgesia. Neurosci. Res., 2000, 38, 113-116.
156. Mitrovic, I.; Margeta-Mitrovic, M.; Bader, S.; Stoffel, M.; Jan, L.Y.; Basbaum, A.I. Contribution of GIRK2-mediated postsynaptic signaling to opiate and a2-adrenergic analgesia and analgesic sex differences. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 271-276.
157. + channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia. J. Neurosci., 2004, 24, 2806-2812.
158. Enna, S.J.; McCarson, K.E. The role of GABA in the mediation and perception of pain. Adv. Pharmacol, 2006, 54, 1-27.
159. Chieng, B.; Williams, J.T. Increased opioid inhibition of GABA release in nucleus accumbens during morphine withdrawal. J. Neurosci., 1998, 18(17), 7033-7039
160. Shoji, Y.; Delfs, J.; Williams, J.T. Presynaptic inhibition of GABA(B)-mediated synaptic potentials in the ventral tegmental area during morphine withdrawal. J. Neurosci., 1999, 19(6), 2347-2355.
161. Madhavan, A.; He, L.; Stuber, G.D.; Bonci, A.; Whistler, J.L. Mu-opioid receptor endocytosis prevents adaptations in ventral tegmental area GABA transmission induced during naloxone-precipitated morphine withdrawal. J. Neurosci., 2010, 30(9), 3276-3286.
162. 2+ channels. J. Neurosci., 1995, 15, 4124-4132.
163. Bagley, E.E.; Gerke, M.B.; Vaughan, C.W.; Hack, S.P.; Christie, M.J. GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal. Neuron, 2005, 45, 433- 445.
164. Laviolette, S.R.; Gallegos, R.A.; Henriksen, S.J.; van der Kooy, D. Opiate state controls bi-directional reward signaling via GABA(A) receptors in the ventral tegmental area. Nat. Neurosci., 2004, 7, 160-169.
165. Vargas-Perez, H.; Kee, R.T.; Walton, C.H.; Hansen, D.M.; Razavi, R.; Clarke, L.; Bufalino, M.R.; Allison, D.W.; Steffensen, S.C.; van der Kooy, D. Ventral tegmental area BDNF induces an opiate-dependent-like reward state in naive rats. Science, 2009, 324, 1732-1734.
166. Bagley, E.E.; Hacker, J.; Chefer, V.I.; Mallet, C; McNally, G.P.; Chieng, B.C.; Perroud, J.; Shippenberg, T.S.; Christie, M.J. Drug-induced GABA transporter currents enhance GABA release to induce opioid withdrawal behaviors. Nat. Neurosci., 2011, 14(12), 1548-1554.
167. Riahi, E.; Mirzaii-Dizgah, I.; Karimian, S.M.; Sadeghipour, H.R.; Dehpour, A.R. Attenuation of morphine withdrawal signs by a GABAb receptor agonist in the locus coeruleus of rats. Behav. Brain Res., 2009, 196(1), 11-14.
168. Raghavendra, V.; Rutkowski, M.D.; DeLeo, J.A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J. Neurosci., 2002, 22, 9980-9989.
169. Hutchinson, M.R.; Bland, S.T.; Johnson, K.W.; Rice, K.C.; Maier, S.F.; Watkins, L.R. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Scientific World J, 2007, 7, 98-111.
170. Liu, L.; Hutchinson, M.R.; White, J.M.; Somogyi, A.A.; Coller, J.K. Association of IL-1p genetic polymorphisms with an increased risk of opioid and alcohol dependence. Pharmacogenet. Genomics, 2009, 19, 869-876.
171. Hao, S.; Liu S.; Zheng, X.; Zheng, W.; Ouyang, H.; Mata, M.; Fink, D.J. The role of TNFa in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats. Neuropsychopharmacology, 2011, 36, 664-676.
172. Kelschenbach, J.; Barke, R. A.; Roy, S. Morphine withdrawal contributes to T helper cell differentiation by biasing cells toward the Th2 lineage. J. Immunol, 2005, 175, 2655-2665.
173. Vale, W.; Spiess, J.; Rivier, C; Rivier, J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and p-endorphin. Science, 1981, 213, 139-719.
174. Owens, M.J.; Nemeroff, C.B. Physiology and pharmacology of corticotropin releasing factor. Pharmacol. Rev., 1991, 43, 425-473.
175. Zorrilla, E.P.; Koob, G.F. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin. Investig. Drugs, 2004, 13, 799-828.
176. Koob, G.F. A role for brain stress system in addiction. Neuron, 2008, 59, 11-34.
177. Bale, T.L.; Vale, W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol, 2004, 44, 525-557.
178. Iredale, P.A.; Alvaro, J.D.; Lee, Y.; Terwilliger, R.; Chen, Y.P.L.; Duman, R.S. Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J. Neurochem., 2000, 74, 199-208.
179. Contarino, A.; Dellu, F.; Koob, G.F.; Smith, G.W.; Lee, K.F.; Vale, W.; Gold, L.H. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res., 1999, 835, 1-9.
180. Papaleo, F.; Ghozland, S.; Ingallinesi, M.; Roberts, A.J.; Koob, G.F.; Contarino, A. Disruption of the CRF2 receptor pathway decreases the somatic expression of opiate withdrawal. Neuropsychopharmacology, 2008, 33, 2878-2887.
181. Funada, M.; Hara, C; Wada, K. Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system. Eur. J. Pharmacol, 2001, 430(2-3), 277-281.
182. Beckmann, A.M.; Matsumoto, I.; Wilce, P.A. Immediate early gene expression during morphine withdrawal. Neuropharmacol, 1995, 34, 1183-1189.
183. Chieng, B.; Keay, K.A.; Christie, M.J. Increased fos-like immunoreactivity in the periaqueductal gray of anaesthetised rats during opiate withdrawal. Neurosci. Lett., 1995, 183, 79-82.
184. Hayward, M.D.; Duman, R.S.; Nestler, E.J. Induction of the c-fos proto-oncogene during opiate withdrawal in the locus coeruleus and other regions of the rat brain. Brain Res., 1990, 525, 256-266.
185. Rohde, D.S.; Detweiler, D.J.; Basbaum, A.I. Spinal cord mechanisms of opioid tolerance and dependence: Fos-like immunoreactivity increases in subpopulations of spinal cord neurons during withdrawal. Neurosci., 1996, 72, 233-242.
186. Stornetta, R.L.; Norton, F.E.; Guyenet, P.G. Autonomic areas of rat brain exhibit increased Fos-like immunoreactivity during opiate withdrawal in rats. Brain Res., 1993, 624, 19-28.
187. Rasmussen, K.; Brodsky, M.; Inturrisi, C.E. NMDA antagonists and clonidine block c-Fos expression during morphine withdrawal. Synapse, 1995, 20, 68-74.
188. Law, P.Y.; Wong, Y.H., Loh, H.H. Molecular mechanisms and regulation of opioid receptor signaling. Annu. Rev. Pharmacol. Toxicol., 2000, 40, 389-430.
189. Garzón, J.; Rodríguez-Muñoz, M.; Sánchez-Blázquez, P. Do pharmacological approaches that prevent opioid tolerance target different elements in the same regulatory machinery? Curr. Drug Abuse Rev., 2008, 1(2), 222-238.
190. Sánchez-Blázquez, P.; Rodríguez-Muñoz, M.; de la Torre-Madrid, E.; Garzón, J. Brain-specific G alphaz interacts with Src tyrosine kinase to regulate Mu-opioid receptor-NMDAR signaling pathway. Cell. Signal., 2009, 21(9), 1444-1454.
191. Liu, Q.; Wang, X.; Liu, Y.; Lu, R.; Yuan, Q.; Yang, B.; Zhou, J.; Wang, Y.; Wang, Z. RACK1 inhibits morphine re-exposure via inhibition of Src. Neurol. Res., 2011, 33(1), 56-62.
192. Walwyn, W.; Evans, C.J.; Hales, T.G. Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J. Neurosci., 2007, 27(19), 5092-104.
193. Hong, M.H.; Xu, C.; Wang, Y.J.; Ji, J.L.; Tao, Y.M.; Xu, X.J.; Chen, J.; Xie, X.; Chi, Z.Q.; Liu, J.G. Role of Src in ligand-specific regulation of delta-opioid receptor desensitization and internalization. J. Neurochem., 2009, 108 (1), 102-114.
194. Loguinov, A.V.; Anderson, L.M.; Crosby, G.J.; Yukhananov, R.Y. Gene expression following acute morphine administration Physiol. Genomics, 2001, 6, 169-181.
195. Stowe, G.N.; Schlosburg, J.E.; Vendruscolo, L.F.; Edwards, S.; Misra, K.K.; Schulteis, G.; Zakhari, J.S.; Koob, G.F.; Janda, K.D. Developing a vaccine against multiple psychoactive targets: a case study of heroin. CNS Neurol Disord Drug Targets, 2011, 10(8), 865-875.
196. Abul-Husn, N.S.; Annangudi, S.P.; Ma'ayan, A.; Ramos-Ortolaza, D.L.; Stockton, S.D.Jr.; Gomes, I.; Sweedler, J.V.; Devi, L.A. Chronic morphine alters the presynaptic protein profile: identification of novel molecular targets using proteomics and network analysis. PLoS One, 2011, 6(10), e25535.
197. Ouyang, H.; Liu, S.; Zeng, W.; Levitt, R.C.; Candiotti, K.A.; Haol, S. An Emerging New Paradigmin OpioidWithdrawal: A Critical Role for Glia-Neuron Signaling in the Periaqueductal Gray. The Scientific World Journal, 2012, 1-9.
198. Rehni, A.K.; Singh, N. Ammonium pyrrolidine dithiocarbamate and RS 102895 attenuates opioid withdrawal in vivo and in vitro. Psychopharmacology (Berl.), 2012, 220, 427-438.
199. Rehni, A.K.; Singh, N. Potential involvement of tyrosine phosphatase and calpain-related pathways in opioid withdrawal syndrome in mice. Behav. Pharmacol., 2012, 23 (3), 302-309.
200. Rehni, A.K.; Singh, N.; Rachamalla, M.; Tikoo, K. Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome. Naunyn Schmiedebergs Arch. Pharmacol., 2012, 385(6), 605-619
201. http://clinicaltrials.gov